Defendant

West-Ward

3 cases as defendant.

Cases
3
Active
1
2 closed
Filed
2012–2020
Top venue
E.D. New York
1 case

Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc. et al.

settled
Docket:
2:12-cv-06761
Court:
D.N.J.
Filed:
2012-10-26
Terminated:
2017-04-05
Patents:8263650
π Jazz Pharmaceuticals, Inc.Δ Roxane Laboratories, Inc.Δ Hikma Pharmaceuticals PLCΔ West-Ward

Jazz sued Roxane Laboratories (later Hikma/West-Ward) asserting the '650 patent. The case was consolidated with 2:10-cv-06108 and 2:12-cv-07459 in April 2013, and the consolidated case settled April 5, 2017, granting Hikma/West-Ward an authorized generic of Xyrem beginning Jan. 1, 2023.

Jazz Pharmaceuticals, Inc. et al. v. Roxane Laboratories, Inc. et al.

settled
Docket:
2:10-cv-06108
Patents:785150664724317895059
π Jazz Pharmaceuticals, Inc.π Jazz Pharmaceuticals Ireland LimitedΔ Roxane Laboratories, Inc.Δ Hikma Pharmaceuticals USA, Inc.Δ West-Ward

Lead consolidated Hatch-Waxman action over Xyrem sodium oxybate. The ’506 patent was among the original patents-in-suit, along with the ’431, ’889, ’219, ’059, and the ’730 family. Resolved by settlement with no final judgment on the ’506 patent.